Baili Tianheng (688506.SH): BL-M05D1 for Injection Included in the Breakthrough Therapy Designation List

Zhitong Finance APP News, Baili Tianheng (688506.SH) announced that the company's independently developed innovative biologic drug BL-M05D1 for injection (Claudin18.2 ADC) for patients with CLDN18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJC) who have previously received first-line standard treatment has been included in the breakthrough therapy designation list by the Center for Drug Evaluation of the National Medical Products Administration (referred to as the "CDE").